Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
Authors:
- Dong Soo LeeDLDong Soo Lee
- Yeon Sil KimYKYeon Sil Kim
- Jae Seok CheonJCJae Seok Cheon
- Jin Ho SongJSJin Ho Song
- Seok Hyun SonSSSeok Hyun Son
- Ji Sun JangJJJi Sun Jang
- Young Nam KangYKYoung Nam Kang
- Jing Hyoung KangJKJing Hyoung Kang
- So Lyoung JungSJSo Lyoung Jung
- Ie Ryung YooIYIe Ryung Yoo
- Hong Seok JangHJHong Seok Jang
Open Access
- 12 June 2012
- journal article
- case report
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 85
Abstract
Background: The aim of this study was to report the long-term clinical outcomes of patients who received stereotactic body radiotherapy (SBRT) as a boost treatment for head and neck cancer. Materials and methods: Between March 2004 and July 2007, 26 patients with locally advanced, medically inoperable head and neck cancer or gross residual tumors in close proximity to critical structures following head and neck surgery were treated with SBRT as a boost treatment. All patients were initially treated with standard external beam radiotherapy (EBRT). SBRT boost was prescribed to the median 80% isodose line with a median dose of 21 (range 10–25) Gy in 2–5 (median, 5) fractions. Results: The median follow-up after SBRT was 56 (range 27.6 − 80.2) months. The distribution of treatment sites in 26 patients was as follows: the nasopharynx, including the base of the skull in 10 (38.5%); nasal cavity or paranasal sinus in 8 (30.8%); periorbit in 4 (15.4%); tongue in 3 (11.5%); and oropharyngeal wall in 1 (3.8%). The median EBRT dose before SBRT was 50.4 Gy (range 39.6 − 70.2). The major response rate was 100% with 21 (80.8%) complete responses (CR). Severe (grade ≥ 3) late toxicities developed in 9 (34.6%) patients, and SBRT boost volume was a significant parameter predicting severe late complication. Conclusions: The present study demonstrates that a modern SBRT boost is a highly efficient tool for local tumor control. However, we observed a high frequency of serious late complications. More optimized dose fractionation schedule and patient selection are required to achieve excellent local control without significant late morbidities in head and neck boost treatment.Keywords
This publication has 18 references indexed in Scilit:
- Excellent Local Control With Stereotactic Radiotherapy Boost After External Beam Radiotherapy in Patients With Nasopharyngeal CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Radical Radiotherapy in Head and Neck Squamous Cell Carcinoma: An Analysis of Prognostic and Therapeutic FactorsClinical Oncology, 2006
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2006
- A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neckBMC Cancer, 2006
- Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2003
- Reirradiation: a potentially curative approach to locally or regionally recurrent head and neck cancerCurrent Opinion in Oncology, 2002
- Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized TrialJournal of Clinical Oncology, 2002
- Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapyCancer, 1985
- Dose-response analysis for nasopharyngeal carcinoma. An historical perspectiveCancer, 1982